MedPath

ENZYCHEM LIFESCIENCES CORPORATION

πŸ‡°πŸ‡·South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo EC-18
First Posted Date
2024-07-05
Last Posted Date
2024-11-08
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
150
Registration Number
NCT06487000

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Phase 2
Conditions
Covid19 Pneumonia
Interventions
Drug: Placebo
First Posted Date
2020-09-29
Last Posted Date
2021-06-10
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
60
Registration Number
NCT04569227
Locations
πŸ‡ΊπŸ‡Έ

Lincoln Medical Center, Bronx, New York, United States

πŸ‡ΊπŸ‡Έ

Kent County Memorial Hospital, Warwick, Rhode Island, United States

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Placebo EC-18
First Posted Date
2020-08-05
Last Posted Date
2022-02-10
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
63
Registration Number
NCT04500132
Locations
πŸ‡°πŸ‡·

Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Phase 2
Completed
Conditions
Stomatitis
Interventions
Drug: Placebo
First Posted Date
2017-06-27
Last Posted Date
2023-07-27
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
105
Registration Number
NCT03200340
Locations
πŸ‡ΊπŸ‡Έ

Cancer Center of Kansas, Wichita, Kansas, United States

πŸ‡ΊπŸ‡Έ

NorthShore University HealthSystem, Evanston, Illinois, United States

πŸ‡ΊπŸ‡Έ

Veterans Affairs Long Beach Health Care System, Long Beach, California, United States

and more 16 locations

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

Phase 1
Completed
Conditions
Febrile Neutropenia
Interventions
First Posted Date
2017-04-07
Last Posted Date
2023-08-15
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
28
Registration Number
NCT03104595
Locations
πŸ‡°πŸ‡·

Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of

πŸ‡°πŸ‡·

National Cancer Center, Gyeonggi-do, Korea, Republic of

πŸ‡°πŸ‡·

Asan Medical Center, Seoul, Korea, Republic of

Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers

Phase 1
Completed
Conditions
Chemotherapy-Induced Neutropenia
Interventions
Dietary Supplement: high-fat diet
First Posted Date
2016-03-07
Last Posted Date
2016-03-15
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
36
Registration Number
NCT02700360
Locations
πŸ‡°πŸ‡·

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

Phase 1
Completed
Conditions
Chemotherapy-Induced Neutropenia
Interventions
Drug: Placebo
First Posted Date
2015-08-26
Last Posted Date
2016-01-27
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
64
Registration Number
NCT02532712
Locations
πŸ‡°πŸ‡·

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

A Safety and PK Study of EC-18 in Healthy Subjects

Phase 1
Completed
Conditions
Chemotherapy-induced Neutropenia
Interventions
Drug: Placebo
First Posted Date
2015-07-14
Last Posted Date
2016-01-11
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
33
Registration Number
NCT02496143
Locations
πŸ‡ΊπŸ‡Έ

Carolina Phase I Clinical Research, Raleigh, North Carolina, United States

Β© Copyright 2025. All Rights Reserved by MedPath